Pharmaron Beijing Co., Ltd. Class A · SZSE:300759
Pharmaron Beijing Co., Ltd. Class A — Q1 2022 Earnings Presentation
10 slides from Pharmaron Beijing Co., Ltd. Class A's earnings presentation, Apr 29, 2022
Slide 1: First Quarterly Results
Stock Code：300759.SZ/3759.HK 2022 First Quarterly Results April 2022
Slide 2: Disclaimer
Disclaimer The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Com
Slide 3: 2022 First Quarterly Financial Performances
2022 First Quarterly Financial Performances The average exchange rate of USD against RMB depreciated by about 2.0% compared with the same period of last year. If the same weighted average USD exchange rate of 2021Q1 was used, the y-o-y revenue growth will be 42.8% in 2022Q1, gross profit growth
Slide 4: Laboratory Services
Robust Growth and Profitability Across All Business Segments: Laboratory Services Revenue growth drivers: Increased demand for our services from existing customers; Deepened integration between bioscience and laboratory platform; Increased customer interest in our integrated IND enabling solution.
Slide 5: CMC (Small Molecule CDMO) Services
Robust Growth and Profitability Across All Business Segments: CMC ( Small Molecule CDMO ) Services Revenue growth drivers: Strong demand for our CMC services with increased number of projects and strengthened pipeline; Successful integration of our CMC operations in China and UK. Gross margin dr
Slide 6: Clinical Development Services
Robust Growth and Profitability Across All Business Segments: Clinical Development Services Revenue growth drivers: Increase in the brand recognition of the domestic clinical development services; efforts in cross-selling to existing customers from both overseas and China. Gross margin drivers:
Slide 7: Biologics and CGT Services
Robust Growth and Profitability Across All Business Segments: Biologics and CGT Services Biologics and CGT business segments began independent accounting during 2021. High operating cost for the newly acquired gene therapy CDMO services capabilities (Pharmaron Biologics (UK) Ltd) in Liverpool.
Slide 8: Operational Efficiency Contributing to Steady Margin Improvement
Operational Efficiency Contributing to Steady Margin Improvement SG&A Expenses as % of Total Revenue Research and Development Cost as % of Total Revenue 17.1% 2.1% 16.7% 2.0% 2.0% 1.9% 16.3% 16.0% 1.7% 15.1% 15.3% 14.3% 1.0% 1.1% 2017 2018 2019 2020 2021 3M2021 3M2022 2017 2018 2019 2020 2021 3M2021
Slide 9: Outstanding Working Capital Management Capabilities
Outstanding Working Capital Management Capabilities Trade Receivables and Contract Assets Turnover(1) Trade Payables Turnover(2) Days Days 78.5 77.7 21.4 74.1 75.2 19.1 65.6 65.1 18.1 18.4 17.3 16.8 2017 2018 2019 2020 2021 3M2022 2017 2018 2019 2020 2021 3M2022 Inventories Turnover(2) Contract Cost
Slide 10: Thank You
a2 & %, 1h PHARMARON THANK YOU